Literature DB >> 26588681

Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.

Zachary B Davis1, Martin Felices, Michael R Verneris, Jeffrey S Miller.   

Abstract

Natural killer (NK) cells constitute an important component of the initial immunological response against transformed cells. However, chronic exposure to the tumor microenvironment can fundamentally alter the ability of NK cells to sufficiently control tumor progression. Thus, the adoptive transfer of healthy, functional NK cells as an interventional therapy has been an area of great interest for improving patient outcomes. Recent developments in the field have provided a better understanding of what makes the NK compartment effective against malignant cells. Moreover, there are now multiple potential sources of NK cell products for infusion as well as techniques to manipulate these cells to enhance their antitumor functions. This review explores the advantages and disadvantages of various sources of NK cells as well as prospective therapeutic enhancements to adoptively transferred NK cells.

Entities:  

Mesh:

Year:  2015        PMID: 26588681      PMCID: PMC4763946          DOI: 10.1097/PPO.0000000000000156

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  82 in total

1.  Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Brian S Schwartz; Marcelo J Pando; Jessica Jarjoura; Vanessa A York; Jeffrey P Houchins; Steve Miller; Sang-Mo Kang; Phillip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

2.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

Review 3.  Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.

Authors:  T Tonn; S Becker; R Esser; D Schwabe; E Seifried
Journal:  J Hematother Stem Cell Res       Date:  2001-08

Review 4.  Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.

Authors:  Michael R Verneris
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

5.  Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.

Authors:  Mark J Smyth; Nadine Y Crowe; Daniel G Pellicci; Konstantinos Kyparissoudis; Janice M Kelly; Kazuyoshi Takeda; Hideo Yagita; Dale I Godfrey
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

6.  Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Authors:  Michelle K Gleason; Michael R Verneris; Deborah A Todhunter; Bin Zhang; Valarie McCullar; Sophia X Zhou; Angela Panoskaltsis-Mortari; Louis M Weiner; Daniel A Vallera; Jeffrey S Miller
Journal:  Mol Cancer Ther       Date:  2012-10-17       Impact factor: 6.261

7.  Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

Authors:  M J Robertson; K J Cochran; C Cameron; J M Le; R Tantravahi; J Ritz
Journal:  Exp Hematol       Date:  1996-02       Impact factor: 3.084

8.  Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

Authors:  Petter S Woll; Bartosz Grzywacz; Xinghui Tian; Rebecca K Marcus; David A Knorr; Michael R Verneris; Dan S Kaufman
Journal:  Blood       Date:  2009-04-13       Impact factor: 22.113

Review 9.  NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.

Authors:  Karl-Johan Malmberg; Yenan T Bryceson; Mattias Carlsten; Sandra Andersson; Andreas Björklund; Niklas K Björkström; Bettina C Baumann; Cyril Fauriat; Evren Alici; M Sirac Dilber; Hans-Gustaf Ljunggren
Journal:  Cancer Immunol Immunother       Date:  2008-03-04       Impact factor: 6.968

10.  Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection.

Authors:  Qingquan Liu; Yongtao Sun; Suzannah Rihn; Anne Nolting; Peter Nicholas Tsoukas; Stephanie Jost; Kristen Cohen; Bruce Walker; Galit Alter
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

View more
  44 in total

1.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

Review 2.  In celebration of Ruggero Ceppellini: HLA in transplantation.

Authors:  E W Petersdorf
Journal:  HLA       Date:  2017-02       Impact factor: 4.513

Review 3.  Challenges of NK cell-based immunotherapy in the new era.

Authors:  Fang Fang; Weihua Xiao; Zhigang Tian
Journal:  Front Med       Date:  2018-07-25       Impact factor: 4.592

4.  Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.

Authors:  Martin Felices; Todd R Lenvik; Behiye Kodal; Alexander J Lenvik; Peter Hinderlie; Laura E Bendzick; Dawn K Schirm; Michael F Kaminski; Ron T McElmurry; Melissa A Geller; Craig E Eckfeldt; Daniel A Vallera; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2020-07-13       Impact factor: 11.151

5.  Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Authors:  Martin Felices; Behiye Kodal; Peter Hinderlie; Michael F Kaminski; Sarah Cooley; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller; Veronika Bachanova
Journal:  Blood Adv       Date:  2019-03-26

6.  Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes.

Authors:  Gretchen A Hoff; Johannes C Fischer; Katharine Hsu; Sarah Cooley; Jeffrey S Miller; Tao Wang; Michael Haagenson; Stephen Spellman; Stephanie J Lee; Markus Uhrberg; Jeffrey M Venstrom; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-13       Impact factor: 5.742

7.  Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells.

Authors:  Xiaomei Wang; Daniel L Jasinski; Jan L Medina; David M Spencer; Aaron E Foster; J Henri Bayle
Journal:  Blood Adv       Date:  2020-05-12

8.  Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Authors:  Heba H Mostafa; Peter Vogel; Ashok Srinivasan; Charles J Russell
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 9.  Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.

Authors:  May Daher; Katayoun Rezvani
Journal:  Curr Opin Immunol       Date:  2018-03-30       Impact factor: 7.486

Review 10.  Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.

Authors:  Zachary B Davis; Daniel A Vallera; Jeffrey S Miller; Martin Felices
Journal:  Semin Immunol       Date:  2017-09-05       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.